NEW YORK (GBI Research), 1 May 2012 - The conversion of prescription drugs to over-the-counter (OTC) status is becoming a hit among major pharmaceutical companies in developing countries, who are eager to expand their target audience, according to a new report by healthcare intelligence company GBI Research.
The new report* suggests that while the US and Western Europe currently dominate the OTC market, emerging regions are set to drive future growth as non-prescription medications gain popularity worldwide.
OTC drugs can be bought without prescription, and are widely used to treat a variety of minor ailments. Today, over 300,000 OTC medicines and ingredients are available for a broad range of conditions, including high cholesterol, weight management, skin disorders and respiratory infections.
OTC medicines are strictly monitored, and a number of regulatory processes have now been established to enable new and approved products to be reviewed in a clear and transparent manner. Since the late 1970s, over 100 prescription (Rx) products have been switched to OTC, and many more are under review. This change expands product accessibility and optimizes product life-cycle management (PLM). Many large pharmaceutical companies have already made strategic investments in OTC medicines, including Johnson & Johnson, GlaxoSmithKline, Pfizer, and Proctor & Gamble. Whilst their business strategies vary, success stems from a combination of careful product selection, optimal distribution and aggressive marketing.
The market will continue to be driven by a number of external factors, including the increasing and aging global population, emerging consumers, consumer empowerment and education, unmet medical needs, healthcare reforms, and governmental support, as well as companies actively managing their patent exposure, optimizing PLM and maximizing their advertising and marketing opportunities.
In 2010, the global OTC market was valued at an estimated $104 billion, following growth at a CAGR of 6.5% between 2006 and 2010. The US and Western Europe account for nearly 50% of sales, while Japan accounts for around 11%. Emerging economies represent only a small segment of global revenue, but their recent rate of growth supersedes that of more dominant regions. The OTC market is forecast to grow by a CAGR of 4.6% during 2011-2015 to generate global revenue of $124.8 billion. Growth will be driven by new product Rx-to-OTC switches, resulting in increased public access to a broader range of medicines.
*Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
This report examines the key issues influencing the global OTC market and assesses why companies switch Rx drugs to OTC, their business strategies, and the potential challenges and opportunities this creates. It provides an analysis of the global OTC market and forecasts broken down by geography and therapy areas, and discusses the national and international factors which impact the OTC market and companies operating in the OTC market. The report reviews the regulatory landscape in the US, Europe and Japan and highlights recent changes in regulatory procedures and guidelines. Therapy profiles provide a detailed analysis of the leading OTC drug classes, and company profiles provide a detailed analysis of the leading OTC companies. Finally the report discusses the challenges and future opportunities in the OTC market, business strategies and future outlook.
This report was built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com
